Tremelimumab MOA (Mechanism of Action of Imjudo)

Tremelimumab moa imjudo

Tremelimumab is marketed by name, Imjudo. It is a CTLA-4 inhibitor that has been approved for the treatment of unresectable HCC and non-small-cell carcinoma. What is CTLA-4? CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a protein receptor that is expressed on the surface of T-cells (a type of immune cell). It functions as a negative regulator … Read more

IBS Treatment including Latest FDA-Approved Prescription Meds

IBS treatment options

Irritable Bowel Syndrome (IBS) is the most common gastrointestinal disorder. Many over-the-counter treatment options are now available to ease the unpleasant symptoms of IBS. But it often gets confusing to choose the right medicine according to your IBS type. A gastrointestinal (GI) illness called irritable bowel syndrome (IBS) is characterized by recurring episodes of abdominal … Read more

Weight Regain after Stopping Ozempic: What to do?

ozempic weight regain

Ozempic (Semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that helps regulate blood sugar levels and reduce appetite, leading to weight loss. However, once you stop taking the medication, your appetite and blood sugar levels may return to pre-treatment levels, which could cause weight gain. It’s important to remember that weight loss and weight management … Read more

Tysabri (Natalizumab) MOA and Indications

Tysabri (Natalizumab) uses moa

Tysabri contains “Natalizumab” considered an evolution in the management of many autoimmune diseases. It is manufactured by Biogen Company and got FDA approval in 2004. In 2005 the drug was voluntarily withdrawn from the U.S. market when cases of progressive multifocal leukoencephalopathy were reported. However, it was again approved by FDA in 2006 due to … Read more

Tofacitinib Mechanism of Action: Xeljanz MOA

tofacitinib mechanism of action xeljanz moa

Tofacitinib is an oral Janus Kinase Inhibitor. Because of its unique and novel mechanism of action, it is one of the potent JAK Inhibitors. It was approved by the FDA in 2012. It is available in two formulations: Immediate Release as Xeljanz, and The Extended Release Oral Tablets as Xeljanz XR Tofacitinib is a Janus … Read more

Rinvoq (Upadacitinib) Mechanism of Action (MOA)

upadacitinib mechanism of action rinvoq

Upadacitinib is among the novel class of medicines with a unique mechanism of action (MOA). It is available by the brand name, Rinvoq that has been approved in 2019 by the FDA. Among the biological medications, it is one of the few medicines that are available as oral tablet formulations with once-daily dosing. Rinvoq Indications: … Read more